2-(isopropoxy)-4-methylpyrimidine | 1246922-85-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(isopropoxy)-4-methylpyrimidine
• 英文别名: 4-Methyl-2-propan-2-yloxypyrimidine
• CAS: 1246922-85-9
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: QQBWWHBDQLXTRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  异丙醇 、 2-羟基-4-甲基嘧啶盐酸盐 在 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 caesium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 10.83h， 以73%的产率得到2-(isopropoxy)-4-methylpyrimidine
  参考文献：
  名称：

  One-Pot Etherification of Purine Nucleosides and Pyrimidines

  摘要：

  A one-pot synthesis of ethers derived from inosine, guanosine, 2'-deoxyguanosine, and pyrimidinones is described Exposure of the heterocycle to 1H-benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and Cs2CO3 produces a reactive intermediate, which is converted to the desired ether by subsequent addition of an appropriate alcohol or phenol and Cs2CO3. Although rapid formation of HMPA from BOP can occur in the presence of an alcohol and base, as demonstrated by the reaction with methanol, under appropriate conditions these heteroaryl ethers can be efficiently synthesized

  DOI：

  10.1021/ol101655h

文献信息

• Ether Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239920A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了有关制备抑制补体因子D的化合物、使用方法和制备过程，所述化合物包括具有式I的化合物，或其药用可接受的盐或组合物，其中A组上的R12或R13是醚（R32）。本文描述的抑制剂靶向因子D并在替代性补体途径的早期和关键点上抑制或调节补体级联，并减少因子D调节经典和凝集素补体途径的能力。本文描述的因子D抑制剂能够减少过度激活的补体，这与某些自身免疫、炎症和神经退行性疾病、缺血再灌注损伤和癌症有关。
• Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds
  申请人：Yuan Jun

  公开号：US20080267887A1

  公开（公告）日：2008-10-30

  Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds analogues of the formula: wherein R, R 2 , R 5 , E, Z 1 , Z 3 , Z 4 , and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds of the invention bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds, which are useful as probes for the localization of C5a receptors.

  吡咯吡啶、吡咯嘧啶和相关杂环化合物的类似物的公式如下： 其中R，R2，R5，E，Z1，Z3，Z4和Ar在此定义。这些化合物是C5a受体的配体。本发明所述的优选吡咯吡啶、吡咯嘧啶和相关杂环化合物以高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的药物组合物，并且涉及使用这些化合物治疗各种炎症、心血管和免疫系统疾病。此外，本发明提供了标记的吡咯吡啶、吡咯嘧啶和相关杂环化合物，这些化合物可用作C5a受体的定位探针。
• PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS
  申请人：Yuan Jun

  公开号：US20110118273A1

  公开（公告）日：2011-05-19

  Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds analogues of the formula: wherein R, R 2 , R 5 , E, Z 1 , Z 3 , Z 4 , and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds of the invention bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds, which are useful as probes for the localization of C5a receptors.

  吡咯并吡啶、吡咯并嘧啶和相关杂环化合物的类似物的公式为：其中R、R2、R5、E、Z1、Z3、Z4和Ar的定义如下。这些化合物是C5a受体的配体。本发明所述的优选吡咯并吡啶、吡咯并嘧啶和相关杂环化合物以高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的吡咯并吡啶、吡咯并嘧啶和相关杂环化合物，这些化合物可用作C5a受体的定位探针。
• Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators
  申请人：GlaxoSmithKline, LLC

  公开号：US20140249147A1

  公开（公告）日：2014-09-04

  Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided, are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新型的取代双环氮杂杂环类Sirtuin调节化合物及其使用方法。这些Sirtuin调节化合物可用于增加细胞寿命，治疗和/或预防各种疾病和疾病，包括与衰老或压力有关的疾病或疾病、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块性疾病、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或疾病。同时，还提供了包含Sirtuin调节化合物和另一种治疗剂的组合物。
• [EN] SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS<br/>[FR] AZAHÉTÉROCYCLES BICYCLIQUES SUBSTITUÉS ET ANALOGUES COMME MODULATEURS DE LA SIRTUINE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013059587A9

  公开（公告）日：2014-10-23